Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson's disease, licensing a bispecific antibody from South Korea's ABL Bio in a deal that could be ...
UK contract development and manufacturer organisation (CDMO) Oxford Biomedica confirmed this morning it is in talks that could result in the acquisition of rival ABL Europe from France’s Institut ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results